Yet another ten stories on antiviral drug discovery (part D): Paradigms, paradoxes, and paraductions

This review article presents the fourth part (part D) in the series of stories on antiviral drug discovery. The stories told in part D focus on: (i) the cyclotriazadisulfonamide compounds; (ii) the {5‐[(4‐bromophenylmethyl]‐2‐phenyl‐5 H ‐imidazo[4,5‐ c ]pyridine} compounds; (iii) (1 H ,3 H ‐thiazolo[3,4‐ a ]benzimidazole) derivatives; (iv) T‐705 (6‐fluoro‐3‐hydroxy‐2‐pyrazinecarboxamide) and (v) its structurally closely related analogue pyrazine 2‐carboxamide (pyrazinamide); (vi) new strategies for the treatment of hemorrhagic fever virus infections, including, as the most imminent, (vii) dengue fever, (viii) the veterinary use of acyclic nucleoside phosphonates; (ix) the potential (off‐label) use of cidofovir in the treatment of papillomatosis, particularly RRP (recurrent respiratory papillomatosis); and (x) finally, the prophylactic use of tenofovir to prevent HIV infections. © 2009 Wiley Periodicals, Inc. Med Res Rev, 30, No. 4, 667–707, 2010